Closely-held InfoBionic.Ai, a pioneering virtual cardiac telemetry company, is transforming cardiac patient care by equipping healthcare providers with a sophisticated ecosystem of solutions designed to enhance every aspect of remote cardiac monitoring—from patient comfort and data quality to operational efficiency and clinical performance.
“We are the first and only company to deliver a continuous, 6-lead sensor, FDA-cleared diagnostic arrhythmia detection system that harnesses advanced cloud-based machine learning AI analysis and intrinsic business intelligence to support the full spectrum of acuity central to a virtual care world,” Stuart Long, CEO of InfoBionic.Ai, says in an interview with BioTuesdays.
The third-generation MoMe Arc virtual cardiac telemetry platform by InfoBionic.Ai is designed to offer healthcare providers and their cardiac patients a tiered, hospital-grade, near real-time monitoring system. Leveraging advanced AI-enabled analysis, it helps clinicians facilitate proactive cardiac interventions, extract clinically relevant insights, and detect critical cardiac indicators that may be overlooked by conventional monitoring techniques.
MoMe ARC includes the four-in-one MoMe Gateway, a body-worn device supporting Holter, Extended Holter, Event, and MCT studies. This patient-friendly, simple touchscreen interface features a discrete, water-resistant design, symptom reporting, easy surface battery charging, and multicarrier 4G LTE cellular connection from virtually any location, Mr. Long notes.
“The MoMe Gateway removes barriers between providers and patients by enabling continuous communication, capturing and transmitting high-fidelity ECG data via Bluetooth to connected sensors in near real-time for physician review. This facilitates superior arrhythmia monitoring, quicker diagnoses, improved treatment plans, and allows patients to receive care at home,” Mr. Long contends.
The integration of AI into cardiac telemetry has a significant opportunity to enhance clinicians’ abilities to accurately diagnose cardiac conditions with substantial improvements in efficiency, Mr. Long explains. The underlying AI can enable the detection of abnormalities that may elude traditional human analysis. This advancement can foster earlier intervention, accelerate the diagnostic process, and support the development of personalized treatment plans, thereby improving patient outcomes.
“With the MoMe ARC platform, healthcare providers can confidently customize care to nearly any clinical use case, supported by its full disclosure model that has distinguished the company from its inception,” Mr. Long says. “Our industry-leading virtual telemetry solutions set the highest standard in continuous monitoring capabilities, delivering clinical insights that enable proactive and timely cardiac interventions.”
The industry-validated MoMe ARC platform is recognized as the gold standard in remote cardiac care, as evidenced by the adoption of InfoBionic.Ai by Mayo Clinic as one of its portfolio companies in late 2023, following a collaborative agreement with the institution. The collaboration benefits from Mayo Clinic’s expertise in cardiac patient monitoring and AI-ECG, combined with InfoBionic.Ai’s core competency in remote cardiac arrhythmia detection. “Our collaboration with Mayo Clinic represents our enduring commitment to delivering the most advanced remote monitoring solutions available and continuing our history of industry-leading quality in remote ECG monitoring for caregivers and their patients,” Mr. Long says.
In June, 2024, InfoBionic.Ai announced a joint research collaboration with closely-held health technology company Anumana, a portfolio company of nference. The research agreement aims to develop and commercialize the next-generation of remote cardiac care solutions by combining Anumana’s groundbreaking ECG-AI algorithms—developed and validated in collaboration with Mayo Clinic—with InfoBionic.Ai’s MoMe ARC platform. Mr. Long indicates that the companies will continue working in close alignment with Mayo Clinic as they develop the integrated solution and seek regulatory clearance to bring this technology to market. “Our goal is to enable timely interventions and deliver actionable insights to healthcare providers through cutting-edge, AI-driven tools that detect underlying cardiac conditions earlier.”
Moreover, Mr. Long informs that InfoBionic.Ai has partnered with HBox.Ai, whose platform and services enable cardiology practices to offer virtual care services to their patients while generating new recurring revenue streams. The integration of HBox.Ai’s virtual care model with InfoBionic.Ai’s advanced cardiac telemetry provides the cardiovascular care industry with the first-ever integrated AI-driven virtual consult, remote patient monitoring, chronic care, and diagnostic monitoring solution, offering healthcare providers unparalleled clinical insights. “Partnering with HBox.Ai will deliver unmatched value to cardiology practices nationwide by enhancing clinical insights, improving patient engagement, and boosting operational efficiency—ultimately reducing hospitalizations and improving patient outcomes.”
In addition, Mr. Long says that InfoBionic.Ai is advancing cardiology practices’ business intelligence with MoMe Analytics, a solution designed to help cardiologists maximize the potential of their patients’ remote cardiac monitoring data to enhance business decision-making and overall cardiac care. “MoMe Analytics empowers providers to access, understand, and utilize practice and patient data more efficiently to scale business and clinical performance.”
Looking ahead, Mr. Long outlines that InfoBionic.Ai is unwaveringly dedicated to advancing more effective remote cardiac care, “We’re in a new gear in this next phase of growth with many of our original investors still with us—not only sticking with us through all of the start-up growing pains but continuing to further their commitment to the company.”
“We are extremely excited about our potential in the coming years and are well-position to continue pioneering innovative products that align with our mission to provide superior remote cardiac care for all,” he adds.
• • • • •
To connect with InfoBionic.Ai or any other companies featured on BioTuesdays, send us an email at [email protected].
